Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report issued on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald raised their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $4.80 on Wednesday. The company has a market capitalization of $279.35 million, a P/E ratio of -60.00 and a beta of 0.77. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $6.75. The firm’s fifty day simple moving average is $4.97 and its 200-day simple moving average is $5.22.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. The business had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. As a group, sell-side analysts forecast that Vanda Pharmaceuticals will post -0.49 earnings per share for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its stake in Vanda Pharmaceuticals by 18.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 2,425 shares during the period. Panagora Asset Management Inc. increased its stake in shares of Vanda Pharmaceuticals by 4.3% during the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 2,509 shares in the last quarter. Susquehanna Fundamental Investments LLC increased its stake in shares of Vanda Pharmaceuticals by 2.1% during the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock worth $1,625,000 after purchasing an additional 5,994 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter worth about $39,000. Finally, SageView Advisory Group LLC acquired a new position in shares of Vanda Pharmaceuticals during the 1st quarter worth about $34,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.